Stay up to date with the latest Mycovia news, press releases, and more. If you have any questions or comments regarding media inquiries, please reach out to mediarelations@mycovia.com.

11.03.2021

Mycovia Pharmaceuticals Announces Completion of Partner Jiangsu Hengrui Pharmaceuticals’ Phase 3 Clinical Study Evaluating Oteseconazole for Treatment of Acute Vulvovaginal Candidiasis (VVC) in China

Download PDF

09.29.2021

Mycovia Pharmaceuticals Announces Presentations of its Supportive Phase 3 Clinical Study (ultraVIOLET) Evaluating the Safety and Efficacy of Oteseconazole (VT-1161) for the Treatment of Recurrent Vulvovaginal Candidiasis (RVVC) and Susceptibility Testing Against Clinical Isolates at IDWeek 2021 Virtual Conference

Download PDF

07.29.2021

Mycovia Pharmaceuticals, Inc. Announces Presentation of Oteseconazole (VT-1161) Phase 3 Data Demonstrating Safety and Efficacy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC) at the 2021 IDSOG Annual Meeting

Download PDF

07.28.2021

Mycovia Pharmaceuticals, Inc. Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis

Download PDF

06.01.2021

Mycovia Pharmaceuticals, Inc. Submits New Drug Application to the U.S. FDA for Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis

Download PDF